![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
TRANSDERMAL APPROACH OF ANTIDIABETIC DRUG GLIBENCLAMIDE: A REVIEW*Deepak Shrivastava Indore Institute of Pharmacy (IIP) Indore Rau-Pithampur Road Indore (M.P.) India. ABSTRACT Transdermal drug delivery system (TDDS) provides a means to sustain drug release as well as reduce the intensity of action and thus reduce the side effects associated with its oral therapy. Transdermal drugs are self-contained, discrete dosage form . Diabetes Mellitus is a chronic metabolic disorder characterised by high blood glucose concentration hyperglycemia caused by insulin deficiency. often combine with insulin resistance. WHO report- WHO projects 346 million people worldwide has diabetes. In 2004, an estimated 3.4 million people died from consequences of high blood sugar. Glibenclamide is a potent oral sulfonylurea hypoglycemic agent. It has to passess some physiochemical properties which cause capable of facilitating the sorption of drug by the Stratum corneum. Glibenclamide (M.W. 494.004 g/mol) and negligible skin degradation. Therefore controlled released Transdermal prepration of Glibenclamide was prepare to give sustain effect as compared to conventional multiple oral dosing. It is currently available for treating hyperglycemia in Non insulin dependent Diabetes Mellitus (NIDDM-type 2). Keywords: Transdermal drug delivery system, Diabetes Mellitus, Glibenclamide, Antidiabetic agent. [Download Article] [Download Certifiate] |